The design of randomized clinical trials in critically ill patients

被引:32
作者
Hébert, PC
Cook, DJ
Wells, G
Marshall, J
机构
[1] Univ Ottawa, Crit Care Program, Ottawa, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Ottawa, Clin Epidemiol Unit, Ottawa, ON, Canada
[4] McMaster Univ, Dept Epidemiol & Biostat, Hamilton, ON, Canada
关键词
critical care; methodology; randomized trials; study protocols;
D O I
10.1378/chest.121.4.1290
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
There are a number of difficulties in the conduct of randomized trials in tire critically ill. These include difficulties in the definition of diseases and syndromes, a heterogenous population of patients undergoing a variety of therapeutic interventions, and outcomes that may not be able to discriminate between beneficial and risky therapies. Following a brief description of different randomized clinical trials (RCTs) and design philosophies, we outline the effects of different design choices in the complex critical care environment. Once the study topic has been determined to be relevant and important, their the potential investigator must establish whether efficacy or effectiveness will be the focus of the RCT. If an effectiveness design philosophy is chosen, their broad representation of study sites, liberal eligibility criteria, easily implemented intervention study protocols, and patient-centered outcomes should be chosen. The potential investigator wishing to establish efficacy will conduct the study in the centers of excellence and adopt stringent eligibility criteria, rigorous study protocols, and opt for outcomes that will be sensitive to change. In conclusion, we describe some of tire major challenges and possible solutions to help a potential investigator through the myriad of difficulties in initiating an RCT in a complex environment.
引用
收藏
页码:1290 / 1300
页数:11
相关论文
共 61 条
[1]   SEPSIS THERAPY TRIALS - CONTINUED DISAPPOINTMENT OR REASON FOR HOPE [J].
ABRAHAM, E ;
RAFFIN, TA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1876-1878
[2]  
AMAHA K, 1989, INTENSIVE CARE WORLD, V6, P59
[3]  
[Anonymous], 1988, LANCET, V2, P349
[4]  
[Anonymous], 2013, Clinical trials: a practical approach
[5]  
ARMITAGE P, 1982, STATISTICIAN, V31, P119
[6]  
ARMITAGE P, 1975, ANONYMOUS SEQUENTIAL, P23
[7]   The effects of ibuprofen on the physiology and survival of patients with sepsis [J].
Bernard, GR ;
Wheeler, AP ;
Russell, JA ;
Schein, R ;
Summer, WR ;
Steinberg, KP ;
Fulkerson, WJ ;
Wright, PE ;
Christman, BW ;
Dupont, WD ;
Higgins, SB ;
Swindell, BB .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :912-918
[9]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[10]   SEPSIS, SEPSIS SYNDROME, AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) - GULLIVER IN LAPUTA [J].
BONE, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (02) :155-156